Keralam's KARE (Kerala United Against Rare Diseases) programme has replaced Roche's Evrysdi with Natsmart, a generic risdiplam made by Natco Pharma, for patients with Spinal Muscular Atrophy (SMA).
The row broke on 22 October 2026, when three former health ministers alleged that children had been given clinical-trial drugs, after bottles labelled "physician's sample / for clinical trial" reached patients at SAT Hospital, Thiruvananthapuram.
The government and SAT Hospital say the switch followed an expert committee's recommendation; Evrysdi costs about Rs 5.2 lakh a bottle against about Rs 16,000 for Natsmart.
The Kerala High Court let the tender proceed on 30 September 2026; the Delhi High Court had refused Roche an interim injunction against Natco in October 2025.
Under the National Policy for Rare Diseases, 2021, SMA is a Group 3 rare disease, eligible for up to Rs 50 lakh of central support at a Centre of Excellence.
An inherited disorder in which motor neurons of the spinal cord and lower brainstem degenerate because the SMN1 gene cannot make enough survival motor neuron (SMN) protein. Muscles near the trunk weaken and waste first. Types 1-4 are graded by age of onset; Type 1 is the most severe.
Simple Analogy: Like cut telephone wires between brain and muscles — the order is sent but never arrives.
| Drug | Type and route | Maker |
|---|---|---|
| Risdiplam (Evrysdi; generic Natsmart) | Oral small molecule that modifies SMN2 splicing to raise SMN protein; daily, lifelong | Roche (generic: Natco) |
| Nusinersen (Spinraza) | Antisense oligonucleotide injected into the spinal fluid (intrathecal); repeated doses | Biogen |
| Onasemnogene abeparvovec (Zolgensma) | One-time gene therapy delivering a working SMN1 gene; intravenous | Novartis |
Places SMA in Group 3 (definitive but very costly, lifelong treatment); central support of up to Rs 50 lakh per patient for treatment at a notified Centre of Excellence (13 CoEs as of February 2025)
Roche holds a patent on risdiplam and its infringement suit against Natco is pending; the Delhi High Court refused an interim injunction in October 2025, letting Natco manufacture the generic
Govern clinical trials and drug approvals through CDSCO — the frame for the 'clinical trial' allegation and for Natco's claim that an oral solution needs no in vivo bioequivalence study
Delhi High Court refuses Roche an interim injunction against Natco's risdiplam
KARE extends free risdiplam to SMA Type 2 patients up to 25 years
Keralam decides to procure generic risdiplam
Kerala High Court declines Cure SMA Foundation's plea to keep the innovator drug; tender proceeds
Former health ministers allege a clinical trial on children; SAT Hospital defends the switch
GS Paper II > Health; GS Paper III > Biotechnology, IPR and access to medicines
General Science > Human diseases and genetic disorders
A drug with the same active ingredient, strength and dosage form as the innovator brand, sold after or despite patent protection
Evidence that a generic delivers the active ingredient into the body at the same rate and extent as the reference drug
A disease affecting a small share of the population, often genetic, with few or costly treatments